SI
SI
discoversearch

Biotech / Medical
MGNX -- MacroGenics
An SI Board Since November 2013
Posts SubjectMarks Bans Symbol
109 26 0 MGNX
Emcee:  scaram(o)uche Type:  Moderated
CD123-related abstract (preclinical) coming up at ASH, so maybe it's time for a thread. DART is a very old concept.... I was one of the first to try it, but the original concept came from Dartmouth and served as the foundation science for Medarex.

MGD006, Servier has right to license for some geographies.....

ash.confex.com

One more ASH abstract, not from MGNX.......

ash.confex.com

Pointer to the pipeline chart, website.....

macrogenics.com

Go!
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
109 Note that Cohen was, and is not a registered lobbyist... newyorker.com <i&nigel bates-May 10
108Listen to the respond to ND MACE boundary end point analysts? TERRIBLE!!!!!!Miljenko Zuanic-May 9
107OFF TOPIC Can anyone explain to me US policy (I may not be literal in English lMiljenko Zuanic-May 9
106 >> We may not be able to respond to @mentions and replies that...... Ascaram(o)uche-May 9
105The agreement was for a term of one year, and paid Essential Consultants 100,000scaram(o)uche-May 9
104It is hard to satisfy appetite of the Tramp's machinery. Is he blackmailing Miljenko Zuanic-May 9
103Novartis apparently didn't pay Cohen enough.scaram(o)uche-May 9
102Agreed!scaram(o)uche-May 8
101One way or another, drug cost-control (as well as cost of development) need to bMiljenko Zuanic-May 8
100 >> stock sunk << We've been waiting for the drug cost-controlscaram(o)uche-May 8
99And clarity did not improve after 1Q cc. INCY transferred IND for MGA012, but wMiljenko Zuanic-May 8
98Secondary: Did they have "advance" knowledge about Ido-1 failure at INMiljenko Zuanic-April 12
97Was secondary so necessary to price it at 21.25???? I do not like this at all!!Miljenko Zuanic-March 28
96But, close to 15% decline, due to secondary, was not what I was looking for!Miljenko Zuanic-March 27
95It was about time, finance.yahoo.com. Miljenko Zuanic-March 26
94 >> SUCKER << Bottom feeder, as in catfish. One step down is snaiscaram(o)uche-March 6
93On a contrary note, when guy like Cilinski Lynn , (V.P.), addapt 10b5-1 plan ( 5Miljenko Zuanic-March 5
92On watch for clear above 27.07. [graphic]Alejandroo Green-March 2
914Q CC Incredible, it was "ONE MAN SHOW"! CEO, Scott Koenig, has capaciMiljenko Zuanic2February 27
904Q/2017 report: finance.yahoo.com <MGD019. This DART molecule is designed tMiljenko Zuanic-February 27
89Great, at least they may not follow HALO (or PBYI) steps/path!Miljenko Zuanic-January 23
88Gets past futility analysis, SOPHIA trial.scaram(o)uche-January 23
87Thanks, didn't know about presentation. Looks like it may live on, subset oscaram(o)uche-January 18
86files.shareholder.com <Phase 1b/2 Study of Margetuximab Plus Pembrolizumab iMiljenko Zuanic-January 18
85K-224 preliminary results in abstract: abstracts.asco.org On many occasion (HMiljenko Zuanic-January 16
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.